171.39
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $171.39, with a volume of 336.98K.
It is down -1.47% in the last 24 hours and down -3.15% over the past month.
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$173.68
Open:
$172.91
24h Volume:
336.98K
Relative Volume:
0.26
Market Cap:
$19.12B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
23.04
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
+0.38%
1M Performance:
-3.15%
6M Performance:
+4.78%
1Y Performance:
+23.19%
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DGX
Quest Diagnostics Inc
|
171.26 | 19.90B | 9.54B | 841.00M | 1.02B | 7.44 |
![]()
TMO
Thermo Fisher Scientific Inc
|
402.62 | 156.19B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
189.99 | 141.54B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
515.28 | 41.59B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
111.34 | 32.35B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
139.02 | 23.75B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-02-25 | Initiated | Redburn Atlantic | Buy |
Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-10-24 | Resumed | Jefferies | Buy |
Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
Aug-28-24 | Resumed | Evercore ISI | In-line |
Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
Feb-26-24 | Initiated | Leerink Partners | Market Perform |
Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
Jan-03-24 | Initiated | Barclays | Equal Weight |
Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
Jun-29-23 | Initiated | Piper Sandler | Neutral |
May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
Jan-23-23 | Initiated | Evercore ISI | In-line |
Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
Feb-23-22 | Downgrade | UBS | Buy → Neutral |
Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
May-04-21 | Upgrade | UBS | Neutral → Buy |
Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-21-20 | Upgrade | Argus | Hold → Buy |
Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-08-20 | Initiated | Wells Fargo | Underweight |
Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
Mar-18-19 | Resumed | Credit Suisse | Neutral |
Jan-31-19 | Downgrade | Argus | Buy → Hold |
Jan-17-19 | Initiated | UBS | Neutral |
Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Meeting | DGX Stock News - GuruFocus
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - The Globe and Mail
Is Wall Street Bullish or Bearish on Quest Diagnostics Stock? - Inkl
Is Wall Street Bullish Or Bearish On Quest Diagnostics Stock? - Barchart.com
Quest Diagnostics' $4M Rest Break Settlement Gets Initial OK - Law360
Quest Diagnostics (DGX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics Inc (DGX) Shares Gap Down to $171.44 on May 21 - GuruFocus
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year? - Yahoo Finance
Quest Diagnostics stock hits all-time high of $179.37 By Investing.com - Investing.com Nigeria
Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4) - Quantisnow
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference - PR Newswire
Lung Cancer Diagnostics Market Outlook: Opportunities in Early - openPR.com
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Quest Diagnostics CEO Reveals Future Growth Strategy: Key Insights Coming at William Blair Conference - Stock Titan
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Insider Sell: Mark Delaney Sells Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics Keeps Dividend at $0.80 per Share, Payable July 21 to Shareholders as of July 7 - marketscreener.com
Quest Diagnostics (DGX) Declares Consistent Dividend - GuruFocus
Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 21, 2025 - marketscreener.com
Quest Diagnostics : Forbes Names Quest Diagnostics One of America's Best Large Employers - marketscreener.com
Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo
Should You Continue to Retain DGX Stock in Your Portfolio? - TradingView
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds - PR Newswire
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Bullish on Quest Diagnosis Inc. - The Globe and Mail
This Company Extended Its Post-Earnings Rally to Record Highs - The Globe and Mail
Labcorp beats quarterly profit estimate on diagnostic test demand - Reuters
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Quest Diagnostics to $190 From $182, Keeps Hold Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | - GuruFocus
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):